Other groups have speculated that “key driver chemokines”—for example CXCL10, which is expressed by LECs in several pathological contexts and implicated in metastasis to LNs (28–30, 143)—may be valid targets in diseases including cancer because of their ability to enhance T-cell-dependent anti-cancer immunity (144). The gene discussed is CXCL10; the disease is cancer.